Vericel Corporation (VCEL)

Market Cap	1.80B -19.0%
Revenue (ttm)	276.26M +16.5%
Net Income	16.52M +59.4%
EPS	0.32 +60.0%
Shares Out	50.93M
PE Ratio	110.53
Forward PE	81.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364,326
Open	34.89
Previous Close	35.14
Day's Range	34.83 - 35.52
52-Week Range	28.95 - 45.97
Beta	1.21
Analysts	Strong Buy
Price Target	57.75 (+63.27%)
Earnings Date	May 7, 2026

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 1997
• Employees: 398
• Stock Exchange: NASDAQ
• Ticker Symbol: VCEL
• Website: https://www.vcel.com

Financial Performance

In 2025, Vericel's revenue was $276.26 million, an increase of 16.45% compared to the previous year's $237.22 million. Earnings were $16.52 million, an increase of 59.41%.

Analyst Summary

According to 5 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price target is $57.75, which is an increase of 63.27% from the latest price.

Price Target

$57.75

(63.27% upside)

Analyst Consensus: Strong Buy